TMEM150C
gene geneOn this page
Also known as DRAM4FLJ12993TTN3
Summary
TMEM150C (transmembrane protein 150C, HGNC:37263) is a protein-coding gene on chromosome 4q21.22, encoding Transmembrane protein 150C (B9EJG8). Nonselective cationic channel with high permeability to Ca(2+).
This gene encodes a transmembrane protein component of a mechanosensitve ion channel that is activated by mechanical stimuli in various cell types and confers slowly adapting, mechanically activated currents in dorsal root ganglion neurons. Mechanically activated ion channels are sensors that are critical for hearing, touch, pain, and blood pressure regulation.
Source: NCBI Gene 441027 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 29 total
- MANE Select transcript:
NM_001080506
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:37263 |
| Approved symbol | TMEM150C |
| Name | transmembrane protein 150C |
| Location | 4q21.22 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | DRAM4, FLJ12993, TTN3 |
| Ensembl gene | ENSG00000249242 |
| Ensembl biotype | protein_coding |
| OMIM | 617292 |
| Entrez | 441027 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 4 protein_coding
ENST00000449862, ENST00000454948, ENST00000508701, ENST00000515780
RefSeq mRNA: 3 — MANE Select: NM_001080506
NM_001080506, NM_001353454, NM_001353455
CCDS: CCDS47087
Canonical transcript exons
ENST00000449862 — 8 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001618366 | 82490061 | 82490238 |
| ENSE00001633635 | 82496068 | 82496195 |
| ENSE00001650997 | 82502895 | 82502927 |
| ENSE00001667588 | 82504578 | 82504667 |
| ENSE00001674009 | 82483176 | 82485719 |
| ENSE00001696540 | 82502727 | 82502794 |
| ENSE00001708206 | 82503059 | 82503112 |
| ENSE00002084189 | 82561906 | 82561988 |
Expression profiles
Bgee: expression breadth ubiquitous, 251 present calls, max score 99.00.
FANTOM5 (CAGE): breadth broad, TPM avg 4.8078 / max 173.3095, expressed in 790 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 52856 | 3.9328 | 743 |
| 52860 | 0.3543 | 172 |
| 52859 | 0.2952 | 157 |
| 52857 | 0.2017 | 116 |
| 52858 | 0.0238 | 8 |
Top tissues by expression
255 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| corpus epididymis | UBERON:0004359 | 99.00 | gold quality |
| cauda epididymis | UBERON:0004360 | 98.09 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 95.58 | gold quality |
| caput epididymis | UBERON:0004358 | 93.87 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 93.45 | gold quality |
| kidney epithelium | UBERON:0004819 | 92.94 | silver quality |
| buccal mucosa cell | CL:0002336 | 92.40 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 91.97 | gold quality |
| adrenal cortex | UBERON:0001235 | 91.68 | gold quality |
| cortical plate | UBERON:0005343 | 91.68 | gold quality |
| left adrenal gland | UBERON:0001234 | 91.63 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 91.50 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 91.34 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 90.88 | gold quality |
| bronchial epithelial cell | CL:0002328 | 90.78 | gold quality |
| entorhinal cortex | UBERON:0002728 | 90.73 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 90.59 | silver quality |
| right adrenal gland | UBERON:0001233 | 90.39 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 90.39 | gold quality |
| bronchus | UBERON:0002185 | 90.30 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 89.62 | gold quality |
| parotid gland | UBERON:0001831 | 89.45 | gold quality |
| heart right ventricle | UBERON:0002080 | 89.25 | gold quality |
| adrenal gland | UBERON:0002369 | 89.07 | gold quality |
| endothelial cell | CL:0000115 | 88.98 | gold quality |
| medial globus pallidus | UBERON:0002477 | 88.92 | gold quality |
| primary visual cortex | UBERON:0002436 | 88.78 | gold quality |
| tibia | UBERON:0000979 | 88.52 | gold quality |
| occipital lobe | UBERON:0002021 | 88.21 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 88.17 | gold quality |
Single-cell (SCXA)
Detected in 4 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-38 | yes | 427.95 |
| E-GEOD-81608 | yes | 16.45 |
| E-ANND-3 | yes | 14.21 |
| E-GEOD-99795 | no | 3.39 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
48 targeting TMEM150C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6867-5P | 100.00 | 82.21 | 3464 |
| HSA-MIR-574-5P | 100.00 | 66.01 | 989 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-4789-3P | 99.99 | 70.75 | 2484 |
| HSA-MIR-23A-3P | 99.95 | 74.24 | 3163 |
| HSA-MIR-23B-3P | 99.95 | 74.24 | 3163 |
| HSA-MIR-23C | 99.95 | 73.92 | 3192 |
| HSA-MIR-96-5P | 99.95 | 72.80 | 2140 |
| HSA-MIR-218-5P | 99.93 | 72.22 | 2103 |
| HSA-MIR-335-3P | 99.93 | 73.36 | 4958 |
| HSA-MIR-12133 | 99.92 | 71.82 | 2006 |
| HSA-MIR-10527-5P | 99.91 | 72.28 | 3754 |
| HSA-MIR-1271-5P | 99.91 | 71.99 | 1972 |
| HSA-MIR-605-3P | 99.88 | 69.22 | 1833 |
| HSA-MIR-182-5P | 99.87 | 74.03 | 2589 |
| HSA-MIR-30A-3P | 99.87 | 69.74 | 2928 |
| HSA-MIR-30D-3P | 99.87 | 69.92 | 2917 |
| HSA-MIR-30E-3P | 99.87 | 69.68 | 2942 |
| HSA-MIR-6844 | 99.82 | 70.69 | 2423 |
| HSA-MIR-636 | 99.80 | 69.58 | 1500 |
| HSA-MIR-4679 | 99.76 | 69.19 | 1229 |
| HSA-MIR-4306 | 99.72 | 70.50 | 3630 |
| HSA-MIR-377-5P | 99.70 | 65.28 | 712 |
| HSA-MIR-6086 | 99.70 | 65.38 | 699 |
| HSA-MIR-4530 | 99.69 | 66.47 | 1509 |
| HSA-MIR-4328 | 99.57 | 71.06 | 4094 |
| HSA-MIR-92B-5P | 99.36 | 63.29 | 110 |
| HSA-MIR-4644 | 99.35 | 69.12 | 2514 |
| HSA-MIR-185-5P | 99.35 | 68.60 | 2497 |
| HSA-MIR-942-3P | 98.81 | 69.04 | 876 |
Literature-anchored findings (GeneRIF, showing 2)
- Exploring Piezo1, Piezo2, and TMEM150C in human brain tissues and their correlation with brain biomechanical characteristics. (PMID:38124148)
- Tentonin 3 is a pore-forming subunit of a slow inactivation mechanosensitive channel. (PMID:38850532)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tmem150c | ENSDARG00000069590 |
| mus_musculus | Tmem150c | ENSMUSG00000050640 |
| rattus_norvegicus | Tmem150c | ENSRNOG00000002258 |
| caenorhabditis_elegans | WBGENE00008709 |
Paralogs (4): DRAM1 (ENSG00000136048), DRAM2 (ENSG00000156171), TMEM150A (ENSG00000168890), TMEM150B (ENSG00000180061)
Protein
Protein identifiers
Transmembrane protein 150C — B9EJG8 (reviewed: B9EJG8)
Alternative names: Tentonin 3
All UniProt accessions (3): B9EJG8, D6RAQ9, D6RDW6
UniProt curated annotations — full annotation on UniProt →
Function. Nonselective cationic channel with high permeability to Ca(2+). Component of a mechanosensitive cation channel, confers mechanically activated (MA) currents with slow inactivation kinetics. May contribute to proprioception.
Subcellular location. Cell membrane. Lysosome membrane.
Miscellaneous. Tentonin comes from the Greek ’tentono’ meaning to stretch.
Similarity. Belongs to the DRAM/TMEM150 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| B9EJG8-1 | 1 | yes |
| B9EJG8-2 | 2 |
RefSeq proteins (3): NP_001073975, NP_001340383, NP_001340384 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR019402 | CWH43_N | Domain |
| IPR050911 | DRAM/TMEM150_Autophagy_Mod | Family |
Pfam: PF10277
Catalyzed reactions (Rhea), 4 shown:
- K(+)(in) = K(+)(out) (RHEA:29463)
- Ca(2+)(in) = Ca(2+)(out) (RHEA:29671)
- Mg(2+)(in) = Mg(2+)(out) (RHEA:29827)
- Na(+)(in) = Na(+)(out) (RHEA:34963)
UniProt features (17 total): topological domain 7, transmembrane region 6, sequence conflict 2, chain 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-B9EJG8-F1 | 91.57 | 0.83 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 89 (showing top):
GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, GOCC_VACUOLAR_MEMBRANE, GOBP_CELLULAR_RESPONSE_TO_EXTERNAL_STIMULUS, GOZGIT_ESR1_TARGETS_DN, CHANDRAN_METASTASIS_DN, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS, CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN, GOBP_SENSORY_PERCEPTION, GOBP_NEUROMUSCULAR_PROCESS_CONTROLLING_POSTURE, CUI_TCF21_TARGETS_2_DN, GOBP_NEUROMUSCULAR_PROCESS, GOBP_TRANSMEMBRANE_TRANSPORT, GOBP_RESPONSE_TO_MECHANICAL_STIMULUS, CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP
GO Biological Process (3): proprioception (GO:0019230), cellular response to mechanical stimulus (GO:0071260), monoatomic cation transmembrane transport (GO:0098655)
GO Molecular Function (1): mechanosensitive monoatomic cation channel activity (GO:0140135)
GO Cellular Component (5): lysosomal membrane (GO:0005765), plasma membrane (GO:0005886), lysosome (GO:0005764), endomembrane system (GO:0012505), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| sensory perception | 1 |
| neuromuscular process controlling posture | 1 |
| response to mechanical stimulus | 1 |
| cellular response to abiotic stimulus | 1 |
| cellular response to external stimulus | 1 |
| monoatomic cation transport | 1 |
| monoatomic ion transmembrane transport | 1 |
| monoatomic cation channel activity | 1 |
| mechanosensitive monoatomic ion channel activity | 1 |
| lysosome | 1 |
| lytic vacuole membrane | 1 |
| membrane | 1 |
| cell periphery | 1 |
| lytic vacuole | 1 |
| vacuole | 1 |
| plasma membrane | 1 |
Protein interactions and networks
STRING
400 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TMEM150C | PIEZO1 | Q92508 | 667 |
| TMEM150C | PIEZO2 | Q9H5I5 | 623 |
| TMEM150C | TMEM120A | Q9BXJ8 | 542 |
| TMEM150C | TMEM221 | A6NGB7 | 484 |
| TMEM150C | PHACTR2 | O75167 | 472 |
| TMEM150C | GPRC5C | Q9NQ84 | 447 |
| TMEM150C | KCNK2 | O95069 | 435 |
| TMEM150C | TRPV4 | Q9HBA0 | 425 |
| TMEM150C | LHFPL7 | Q6ICI0 | 420 |
| TMEM150C | TMEM87A | Q8NBN3 | 413 |
| TMEM150C | GPR137C | Q8N3F9 | 410 |
| TMEM150C | TMEM63C | Q9P1W3 | 399 |
| TMEM150C | OVOL3 | O00110 | 390 |
| TMEM150C | TMEM132E | Q6IEE7 | 387 |
| TMEM150C | ASIC2 | Q16515 | 378 |
IntAct
0 interactions, top by confidence:
BioGRID (15): TMEM150C (Affinity Capture-RNA), TMEM150C (Positive Genetic), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), TMEM150C (Co-fractionation), USP39 (Co-fractionation)
ESM2 similar proteins: A2AE42, A3A9H6, A5D7C9, A5D9A7, A6NM10, B3SHH9, B5DFH9, B9EJG8, F1NZP5, O14569, P10897, P49447, P82352, Q08DE1, Q14714, Q148G2, Q3ZCD2, Q5E965, Q5ND56, Q5RCZ2, Q5U2W7, Q5ZJX0, Q60720, Q62147, Q641Y1, Q6GPL4, Q6P0C6, Q6P1H1, Q71RH2, Q7TNV1, Q80ZE4, Q86TG1, Q8BMD6, Q8C8S3, Q8IXF9, Q8N8Q1, Q8NBI2, Q8TBR7, Q8VHW3, Q8VHW7
Diamond homologs: A5D7C9, A6NC51, A9JSP6, B5DFH9, B9EJG8, Q28BP2, Q32PK2, Q3ZC48, Q4V7T3, Q4V7T7, Q6UX65, Q8C8S3, Q8R218, A7MBB3, Q5BK09, Q6GPL4, Q86TG1, Q91WN2, Q9CR48, Q9DC58, Q9QZE9, Q8N682, Q5EAK8, Q6NRS6
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
29 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 23 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1836 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 4:82502793:TG:T | acceptor_gain | 1.0000 |
| 4:82502796:T:C | acceptor_gain | 1.0000 |
| 4:82502796:T:TC | acceptor_gain | 1.0000 |
| 4:82504570:ATACT:A | donor_loss | 1.0000 |
| 4:82504571:TAC:T | donor_loss | 1.0000 |
| 4:82504572:AC:A | donor_loss | 1.0000 |
| 4:82504573:CTCA:C | donor_loss | 1.0000 |
| 4:82504575:C:CC | donor_loss | 1.0000 |
| 4:82504576:A:AC | donor_gain | 1.0000 |
| 4:82504577:C:CC | donor_gain | 1.0000 |
| 4:82504577:CA:C | donor_gain | 1.0000 |
| 4:82504577:CACT:C | donor_gain | 1.0000 |
| 4:82504663:TACCA:T | acceptor_gain | 1.0000 |
| 4:82504664:ACCA:A | acceptor_gain | 1.0000 |
| 4:82504665:CCA:C | acceptor_gain | 1.0000 |
| 4:82504665:CCAC:C | acceptor_gain | 1.0000 |
| 4:82504666:CA:C | acceptor_gain | 1.0000 |
| 4:82504666:CAC:C | acceptor_gain | 1.0000 |
| 4:82504668:C:CC | acceptor_gain | 1.0000 |
| 4:82504668:CTGAA:C | acceptor_loss | 1.0000 |
| 4:82490118:T:A | donor_gain | 0.9900 |
| 4:82490240:T:C | acceptor_gain | 0.9900 |
| 4:82495752:AAC:A | donor_gain | 0.9900 |
| 4:82502722:CTTA:C | donor_loss | 0.9900 |
| 4:82502724:TACCT:T | donor_loss | 0.9900 |
| 4:82502790:CAATG:C | acceptor_gain | 0.9900 |
| 4:82502792:ATG:A | acceptor_gain | 0.9900 |
| 4:82502795:C:CC | acceptor_gain | 0.9900 |
| 4:82502926:TC:T | acceptor_gain | 0.9900 |
| 4:82502927:CC:C | acceptor_gain | 0.9900 |
AlphaMissense
1627 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 4:82496071:A:C | F120L | 1.000 |
| 4:82496071:A:T | F120L | 1.000 |
| 4:82496073:A:G | F120L | 1.000 |
| 4:82496093:C:T | G113E | 1.000 |
| 4:82485667:C:A | W198C | 0.999 |
| 4:82485667:C:G | W198C | 0.999 |
| 4:82485669:A:G | W198R | 0.999 |
| 4:82485669:A:T | W198R | 0.999 |
| 4:82490169:A:G | W145R | 0.999 |
| 4:82490169:A:T | W145R | 0.999 |
| 4:82490183:C:T | G140D | 0.999 |
| 4:82490207:C:A | G132V | 0.999 |
| 4:82490207:C:T | G132E | 0.999 |
| 4:82490208:C:G | G132R | 0.999 |
| 4:82490208:C:T | G132R | 0.999 |
| 4:82490217:G:C | H129D | 0.999 |
| 4:82496074:A:C | N119K | 0.999 |
| 4:82496074:A:T | N119K | 0.999 |
| 4:82496078:C:A | G118V | 0.999 |
| 4:82496078:C:T | G118D | 0.999 |
| 4:82496079:C:G | G118R | 0.999 |
| 4:82496093:C:A | G113V | 0.999 |
| 4:82496094:C:G | G113R | 0.999 |
| 4:82496094:C:T | G113R | 0.999 |
| 4:82496174:C:G | R86P | 0.999 |
| 4:82502743:G:C | N73K | 0.999 |
| 4:82502743:G:T | N73K | 0.999 |
| 4:82502758:A:C | F68L | 0.999 |
| 4:82502758:A:T | F68L | 0.999 |
| 4:82502760:A:G | F68L | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000029670 (4:82528846 G>A), RS1000044853 (4:82523290 A>G), RS1000065033 (4:82530295 A>C,T), RS10001408 (4:82507270 T>C), RS1000160956 (4:82535679 G>C), RS1000174255 (4:82492132 G>C,T), RS1000229580 (4:82499655 G>A), RS10002527 (4:82508700 A>T), RS1000274159 (4:82542021 C>T), RS1000285945 (4:82492113 G>A,T), RS1000294917 (4:82498985 CTT>C), RS1000328805 (4:82549603 A>G), RS1000346980 (4:82499332 G>T), RS1000358140 (4:82529074 G>A), RS1000375933 (4:82542954 A>G)
Disease associations
OMIM: gene MIM:617292 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
28 total (human), top 28 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | increases expression | 3 |
| Phenylmercuric Acetate | affects cotreatment, decreases expression | 2 |
| S-(1,2-dichlorovinyl)cysteine | affects cotreatment, decreases expression, affects response to substance, increases expression | 1 |
| mercuric bromide | decreases expression, affects cotreatment | 1 |
| perfluoro-n-nonanoic acid | decreases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | decreases expression, affects cotreatment | 1 |
| abrine | decreases expression | 1 |
| Grape Seed Proanthocyanidins | affects cotreatment, decreases expression | 1 |
| dorsomorphin | affects cotreatment, decreases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Vehicle Emissions | decreases expression | 1 |
| Benzo(a)pyrene | affects methylation, increases methylation | 1 |
| Cadmium | decreases expression, increases abundance | 1 |
| Catechin | decreases expression, affects cotreatment | 1 |
| Coumestrol | decreases expression | 1 |
| Diethylhexyl Phthalate | decreases expression | 1 |
| Dimethyl Sulfoxide | affects expression | 1 |
| Estradiol | decreases expression | 1 |
| Fluorouracil | decreases expression | 1 |
| Lipopolysaccharides | affects cotreatment, decreases expression, affects response to substance, increases expression | 1 |
| Silicon Dioxide | decreases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Tretinoin | increases expression | 1 |
| Triclosan | decreases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Cadmium Chloride | decreases expression, increases abundance | 1 |
| Okadaic Acid | decreases expression | 1 |
| Particulate Matter | affects expression | 1 |
Cellosaurus cell lines
2 cell lines: 2 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_TS79 | HAP1 TMEM150C (-) 1 | Cancer cell line | Male |
| CVCL_TS80 | HAP1 TMEM150C (-) 2 | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.